Study #2024-0092
Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients: the GIV-IN PV TRIAL
MD Anderson Study Status
Enrolling
Treatment Agent
Givinostat, Hydroxyurea
Description
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Polycythemia Vera
Study phase:
Phase III
Physician name:
Lucia Masarova
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.